CVRX stock edges higher as investors watch neuromodulation growth
Published on 09/05/2026 at 17:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CVRx stock (ISIN US12674F1003) closed at 3.05 USD on September 4, 2026, up 1.33% from the previous session according to market data from Yahoo Finance, providing a fresh reference point for investors looking at the Minneapolis-based neuromodulation specialist.
Recent price move and market context
As of September 4, 2026, CVRx stock traded at 3.05 USD at the close on its primary listing in the United States, with a slight after-hours uptick to 3.09 USD shown in the same overview from Yahoo Finance, highlighting a modest continuation of interest beyond regular hours.
That closing level around 3 USD places the shares in the lower single-digit price zone, which for many retail investors underscores the sensitivity of CVRX to small absolute moves in the quote, since each 0.10 USD shift represents a meaningful percentage change at this price level.
Heart failure focus and revenue backdrop
CVRx, Inc. focuses on implantable neuromodulation devices designed to treat heart failure and related cardiovascular conditions, with its Barostim system positioned as a therapy option for patients whose symptoms are not adequately controlled by medication alone in the evolving US and European cardiology markets.
In its recent financial reporting, CVRX has emphasized revenue growth tied to increased adoption of its therapy across specialized centers, with quarterly updates showing how sales from its Barostim program form the core of its top line and guide expectations for the next phase of commercialization in heart failure treatment.
Further facts and figures on CVRX
Investors can find more detailed regulatory filings and historical performance data for CVRX through the topic overview and the company's own investor relations materials.
Barostim system as a flagship therapy
CVRX's flagship product Barostim is an implantable device that stimulates baroreceptors in the carotid artery to help regulate blood pressure and heart function, targeting patients with chronic heart failure who remain symptomatic despite guideline-directed medical therapy and device interventions.
By positioning Barostim within established treatment pathways and working closely with cardiology centers, CVRX aims to build a recurring revenue base from device sales and related procedures, while also supporting long-term clinical data collection that can underpin broader reimbursement and guideline inclusion.
Stock level and investor perspective
With CVRX stock closing at 3.05 USD as of September 4, 2026 on its US listing, the shares remain in a range where relatively small absolute price adjustments translate into double-digit percentage moves, making the stock particularly sensitive to new clinical data, reimbursement decisions or broader sentiment toward medtech growth names.
Key data on CVRX stock
- Company: CVRx, Inc.
- ISIN: US12674F1003
- Ticker: CVRX
- Trading venue: NASDAQ
- Price (as of September 4, 2026, 16:00): 3.05 USD
- Sector / Industry: Medical Devices / Cardiovascular
- Index membership: Not part of a major benchmark index
